CD274 and non-small cell lung carcinoma: The outlook for NSCLC has substantially improved in the past 2 decades, partly because of the identification of numerous driver mutations, particularly EGFR mutations, and the recognition of PD-L1 expression as a reliable marker for immunotherapy response in patients without driver mutations.